# A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

> **NCT05472259** · PHASE2 · RECRUITING · sponsor: **Belgian Group of Digestive Oncology** · enrollment: 134 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Nanoliposomal irinotecan
- **DRUG:** 5 FU
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT05472259
- **Lead sponsor:** Belgian Group of Digestive Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472259, "A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05472259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*